首页> 美国卫生研究院文献>Morbidity and Mortality Weekly Report >Progress Toward Measles Elimination — Eastern Mediterranean Region 2013–2019
【2h】

Progress Toward Measles Elimination — Eastern Mediterranean Region 2013–2019

机译:麻疹消除的进展 - 东地中海地区2013-2019

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In 1997, during the 41st session of the Regional Committee for the Eastern Mediterranean, the 21 countries in the World Health Organization (WHO) Eastern Mediterranean Region* (EMR) passed a resolution to eliminate† measles (1). In 2015, this goal was included as a priority in the Eastern Mediterranean Vaccine Action Plan 2016–2020 (EMVAP) (2), endorsed at the 62nd session of the Regional Committee (3). To achieve this goal, the WHO Regional Office for the Eastern Mediterranean developed a four-pronged strategy: 1) achieve ≥95% vaccination coverage with the first dose of measles-containing vaccine (MCV1) among children in every district of each country through routine immunization services; 2) achieve ≥95% vaccination coverage with a second MCV dose (MCV2) in every district of each country either through implementation of a routine 2-dose vaccination schedule or through supplementary immunization activities§ (SIAs); 3) conduct high-quality, case-based surveillance in all countries; and 4) provide optimal measles clinical case management, including dietary supplementation with vitamin A (4). This report describes progress toward measles elimination in EMR during 2013–2019 and updates a previous report (5). Estimated MCV1 coverage increased from 79% in 2013 to 82% in 2018. MCV2 coverage increased from 59% in 2013 to 74% in 2018. In addition, during 2013–2019, approximately 326.4 million children received MCV during SIAs. Reported confirmed measles incidence increased from 33.5 per 1 million persons in 2013 to 91.2 in 2018, with large outbreaks occurring in Pakistan, Somalia, and Yemen; incidence decreased to 23.3 in 2019. In 2019, the rate of discarded nonmeasles cases¶ was 5.4 per 100,000 population. To achieve measles elimination in the EMR, increased visibility of efforts to achieve the measles elimination goal is critically needed, as are sustained and predictable investments to increase MCV1 and MCV2 coverage, conduct high-quality SIAs, and reach populations at risk for not accessing immunization services or living in areas with civil strife.
机译:1997年,在地中海东部地中海区域委员会第41届会议期间,世界卫生组织(世卫组织)东部地中海地区*(EMR)的21个国家通过了决议来消除†麻疹(1)。 2015年,这一目标被列为2016 - 2016年东部地中海疫苗行动计划的优先事项(EMVAP)(2),在区域委员会第62届会议(3)届会议上批准。为了实现这一目标,世卫组织地中海的地区办事处开发了一个四管齐下的战略:1)通过常规,在每个国家的每个地区的儿童中占含有麻疹的第一剂量疫苗(MCV1)的疫苗接种覆盖率达到≥95%免疫服务; 2)通过实施常规2剂疫苗接种时间表或通过补充免疫活动(SIAS),在每个国家的每个地区均达到≥95%的疫苗接种覆盖率3)在所有国家进行高质量,基于案例的监视; 4)提供最佳的麻疹临床案例管理,包括膳食补充维生素A(4)。本报告介绍2013 - 2019年期间EMR中麻疹消除的进展,并更新了之前的报告(5)。估计MCV1覆盖率从2013年的79%增加到2018年的82%。2013年MCV2覆盖率从2018年的59%增加到74%。此外,在2013-2019期间,在SIAS期间收到了大约32640万儿童。报告证实的麻疹发病率从2013年的每100万人33.5增加到2018年的91.2,在巴基斯坦,索马里和也门发生了大量爆发; 2019年发病率降至23.3. 2019年,丢弃的非辐射案件率为每10万人5.4。为了在EMR中消除麻疹,增加了努力实现麻疹消除目标的可见性,这是​​严重需要的,因为持续和可预测的投资增加MCV1和MCV2覆盖,开展高质量的SIAS,并在不访问免疫的风险中达到群体服务或生活在民间冲突中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号